Comparison of Connective Tissue Graft Versus Titanium Papillary Inserts in the Surgical Reconstruction of Interdental Papilla.
Efficacy of Connective Tissue Graft Versus Titanium Papillary Inserts in the Surgical Reconstruction of Interdental Papilla
1 other identifier
interventional
18
1 country
1
Brief Summary
Aim and Objectives: The study aimed to evaluate the effectiveness of titanium inserts for interdental papilla reconstruction, comparing it with the Han and Takei technique using subepithelial connective tissue grafts. The objectives included assessing the black triangle height, papilla height and papilla presence index (PPI) at baseline, 1 month and 3 months post operatively along with the evaluation of Early Wound Healing Score (EHS) during the first week of post operative healing period. Patients and Methods: This single-blind randomized clinical trial included systemically healthy individuals aged 18-35 years with Nordland and Tarnow's Class I-III papillary loss. A total of 18 participants were randomly assigned to either test group or control group. Clinical parameters were measured pre- and post-operatively at specified intervals. Both groups received standard presurgical care and postoperative follow-up. The surgical protocol for the test group involved titanium insert placement in the interdental bone, while the control group received a connective tissue graft using the Han and Takei method.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 21, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 21, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 21, 2025
CompletedFirst Submitted
Initial submission to the registry
August 30, 2025
CompletedFirst Posted
Study publicly available on registry
February 10, 2026
CompletedFebruary 10, 2026
February 1, 2026
1.6 years
August 30, 2025
February 3, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Interdental papilla height
To be measured from base of the papilla (a line joining the two adjacent teeth gingival zenith) to the tip of the papilla. Measured with UNC-15 probe.
3 MONTHS
Black triangle height
Measurement from the tip of the interdental papilla to the apical-most point of the contact point. Measured using a digital vernier caliper.
3 MONTHS
Papilla presence index (PPI)
given by Cardaropoli et al
3 MONTHS
Secondary Outcomes (1)
Early Wound Healing Score (EHS)
1 WEEK
Study Arms (2)
TITANIUM INSERTS FOR PAPILLA RECONSTRUCTION
EXPERIMENTALSUB-EPITHELIAL CONNECTIVE TISSUE GRAFT FOR PAPILLA RECONSTRUCTION USING HAN & TAKEI TECHNIQUE
ACTIVE COMPARATORInterventions
The titanium papillary insert2 is composed of a pyramidal- shaped polished titanium core; it has a height of 2 to 3 mm and a base that is 3 mm bucco-lingually and 1 mm in the mesio-distal dimension. It also has mesial and distal concavities to allow for the emergence of the papilla. It is fitted into the bone between two adjacent teeth by means of a self-taping screw extension that is 0.8 mm in diameter and 5 mm in length.
CTG is widely used across a broad range of clinical indications in periodontal and peri-implant therapy. It is primarily indicated for the treatment of gingival recession, reduction of dentinal hypersensitivity, and correction of mucogingival deformities.
Eligibility Criteria
You may qualify if:
- Systemically healthy male and female patients with a stable periodontal health of age 18-35 years.
- Patients with Nordland and Tarnow's1 Class I, II, III interdental papillary loss at a single site and Gingival recession \< 2 mm on the facial aspect.
- Patients presenting with adequate width of attached gingiva (2-3mm)
- Having a thick gingival biotype (2 mm)
You may not qualify if:
- Midline diastema patients
- Medically compromised patients
- Pregnant and lactating women
- Heavy smokers,
- Patient who underwent radiotherapy \& chemotherapy,
- Patients with any bleeding or clotting disorders
- Patients not willing to participate in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dr R Viswa Chandralead
- SVS Institute of Dental Sciencescollaborator
Study Sites (1)
Svs Institute of Dental Sciences
Mahbūbnagar, Telangana, 509001, India
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- PROFESSOR AND HEAD OF DEPARTMENT
Study Record Dates
First Submitted
August 30, 2025
First Posted
February 10, 2026
Study Start
May 21, 2023
Primary Completion
December 21, 2024
Study Completion
May 21, 2025
Last Updated
February 10, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share